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Abstract
Sclerosis multiplex (multiple sclerosis, MS) is a chronic autoimmune inflammatory disease
of the central nervous system. The immune regulatory defects lead to the process of
inflammation and neurodegenerationthat results in the deterioration of neurological
functions. It is still unclear as to why MS is so devastating and rapidly progressive in one
patient and less so in another. It is known that the etiopathogenesis of MS is very complex,
and many factors can be involved in the risk and character of the disease and its progression.
In this chapter, we discuss the general molecular and cellular mechanisms of action of
genetic and biochemical factors that are related to immune system regulation and thus
can be connected to the individually varying risk and disability progression of MS. We
found that gene variants of the gene polymorphism rs6897932 in interleukin 7 receptor α
chain gene rs10735810 in vitamin D receptor gene and HLA-DR and HLA-DQ genes as
well as the serum level of vitamin D are associated with MS risk or disability progres‐
sion in Central European Slovak population.
Keywords: multiple sclerosis, risk, disability progression, gene polymorphism, bio‐
chemical marker
1. Introduction
In triggering an autoimmune response in multiple sclerosis (MS), environmental factors have
a  strong  effect  and  interact  with  complex  risk-conferring  genetic  variants  [1–3].  In  this
process, the myelin reactive Tcells with altered functional characteristics are formed and
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activated  [4].  The  immune  regulatory  defects  and  increased  migration  of  autoreactive
lymphocytes  within  the  brain,  that  are  the  typical  traits  in  MS,  lead  to  the  process  of
inflammation, myelin sheath breakdown, demyelination, remyelination, neuronal and axonal
degeneration, and subsequent deterioration of neurological functions [5]. Neurodegenera‐
tion, neuronal and axonal damage that correlate with the progression of the disease can be
a process partly independent from inflammation and demyelination or even can be the cause
of demyelination occurring from the disease onset. Axonal damage in MS is a result of many
pathological processes [6, 7].
It is still unclear as to why MS is so devastating and rapidly progressive in one patient and
less so in another. Because the etiopathogenesis of MS is very complex, disease develop‐
ment as well as the characteristics of disease progression is probably the consequence of
multifactorial interaction. Our work is dedicated to genetic and biochemical markers that
were chosen according to their possible role in the modulation of the immune response in
MS patients and thus could be associated with MS risk and disability progression. In our
work, we discuss the immune response-related genetic factors associated with MS that can
be generally classified into HLA genes and non-HLA genes. Since vitamin D can have an
important role in the pathogenesis of MS, great part of our work is dedicated to its metabo‐
lism, functions, mechanisms of action in MS and genetic factors that can modify these effects.
In this work, we also present the results of our own analysis of genetic and biochemical
markers that we found to be associated with MS risk or progression in the group consist‐
ing of MS patients with clinically diagnosed MS and healthy individuals from the region of
Central Slovakia. To evaluate the disease progression rate, we used the widely accepted
multiple sclerosis severity score (MSSS, score range 0.01–9.99) [8] that considers the neuro‐
logical impairment of the functional systems (expanded disability status scale score) [9]
together with disease duration. For the purpose of the association analysis of these mark‐
ers with the rate of disease disability progression, we stratified MS patients by MSSS scores
to three groups—slowly progressing MS (MSSS < 3), mid-rate progressing MS (MSSS 3–6)
and rapidly progressing MS (MSSS > 6) [10].
2. Immune response-related genetic factors in the risk and progression of
multiple sclerosis
MS is a typical gender-dependent disease; a higher risk of MS is observed in women than in
men in all populations and races. A study conducted in Canada found female to male ratio in
individuals affected by MS to be 3:1 [11]. The risk of MS development in siblings of an affected
individual is estimated to be 5%, in children 2%, in monozygotic twins 25% [5]. However, it
has been shown that genetic predisposition is not strong enough to induce disease develop‐
ment, and appropriate environmental triggers are necessary to start the disease process [1,
12]. In general, the MS-associated genes can be classified into genes of the HLA-complex
andnon-HLA genes [3].
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3. Gene polymorphisms and haplotypes in the aetiology of multiple
sclerosis
The single-nucleotide polymorphism (SNP) is a variation of a single nucleotide, which is
present in the population in a frequency higher than 0.01. SNPs are the most common type of
genetic variation and are usually caused by somatic or gametic mutations. Nucleotide change
can cause the formation or loss of restriction sites for bacterial endonucleases that are able to
cleave the specific DNA sequence. The identification of gene polymorphisms that are in
correlation with other risk factors, including biochemical markers, can be useful in establishing
the risk of MS development, prognosis, clinical course of the disease and response to therapy.
Haplotype (haploid genotype) is a certain combination of alleles or SNPs in the sequence of
the DNA, whichis localized on one chromosome and is inherited together. When two alleles
are in linkage disequilibrium, they are inherited together in a higher frequency than expected
randomly [13]. The combination of more alleles, known as tagging SNPs, enables us to identify
the other associated alleles. For example, the allele A of gene polymorphism rs3135388
corresponds to the incidence of allele HLA-DRB1*1501, which is the most common genetic risk
factor for MS development [14–16].
4. HLA genes and MS
Antigen expression that is inducible by cytokines is different on the various immune cells.
Major histocompatibility complex II (MHCII) antigens are transmembrane proteins localized
on the immune cells, thus having an important role in the process of exogenous antigen
presentation to Tcells. MHCII molecules are coded by the gene of human leucocyte antigens
D (HLA-D gene) that is localized on chromosome 6 and has three regions—HLA-DP, HLA-
DQ and HLA-DR [17]. The susceptibility of the population to autoimmune diseases depends
on the individual ability to express HLA-DQ and HLA-DR antigens. This expression can be
induced by virus infection, most likely by EBV, influenza or paramyxovirus [18]. MHCII gene
expression is regulated by vitamin D through its binding to the vitamin D–responsive ele‐
ments(VDREs) that are localized in the promoter region of HLA-DRB1 gene. This fact can
explain the interaction between vitamin D, that is an important factor modifying MS devel‐
opment and disease course, and genetic predisposition to MS represented mainly by a highly
conservative allele HLA-DRB1*1501. HLA-DRB1*1501 allele is in general considered to be the
most important susceptibility allele of MS [19–24]. This allelewas found to be present in over
50% of MS cases [25, 26]. The increased frequencies of the DRB1*15 allele in MS patients have
been described in Northern Europeans [23, 27], South and North Americans [20, 28], Medi‐
terraneans [29, 30] and African Americans [21]. In Spanish cohorts, the DRB1*03 was the second
most frequent allele associated with MS, but only after eliminating HLA-DRB1*15 [29]. The
DRB1*03 allele has also been found to be significantly associated with the increased risk of MS
in Scandinavians [27], Sardinians [31], and Australians [32]. Fernández et al. [33] found that
the DRB1*13 allele is protective against MS development in Spaniards. A protective effect of
the alleles DRB1*01, DRB1*07, DRB1*12 and DRB1*14 was confirmed in the recent meta-
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analysis in Caucasians [24]. The allele DRB1*07 was found to be protective against MS also in
Scandinavians [34]. The DRB1*13.03 allele was found to be the primary risk allele in MS
patients of European descent [23]. The protective effect against MS has also been shown for
the HLA-DRB1*11 allele [24, 29].
The DQB1*06:02 allele was found to be linked to the increased risk of MS with a proved tight
linkage disequilibrium between DRB1*15 and DQB1*06 in Caucasians [35]. As the risk factor
of MS, DQB1*06:02 allele has also been identified in a cohort of Afro-Brazilians [36] and
Spaniards [33]. Kaushansky et al. [37] suggested that the role of the DRB1*15:01 and
DQB1*06:02 alleles in MS depends on the heterogeneous interaction of target antigen, geno‐
type, and phenotype. On the contrary, Isobe et al. [38] found none of the HLA-DQB1 alleles to
be associated with MS in African Americans. According to the combinations of HLA-alleles,
the association of HLA-DRB1*15/*15 genotype with MS was identified by several studies [32,
34, 39]. In multi-case MS families, Barcellos et al. [39] identified a high risk DRB1*15/*08
genotype and protective DRB1*15/*14 genotype. The study of Sawcer et al. [23] indicates that
in all populations of North-European ancestry, a predisposition to MS is linked with the
DRB1*15:01-DQB1*06:02 haplotype. Furthermore, Link et al. [34] in a Scandinavian cohort
showed that risk haplotypes for MS are almost all DRB1*15 bearing haplotypes, while
protective effect against MS development are HLA class I A*02 allele-bearing haplotypes. In
Sardinian MS patients, Cocco et al. [40] confirmed a positive association of the haplotype HLA
DRB1*03:01-DQB1*02:01 with MS.
In the study from our laboratory, we analysed the association of the HLA-DRB1/DQB1 genes,
alleles and their combinations with susceptibility to MS in the population from central
Slovakia. We found that the increased risk of MS is in individuals carrying alleles HLA-
DRB1*15, DRB1*03 and DQB1*06, genotypes HLA-DRB1*15/*15 DQB1*06/*06 and haplotype
DRB1*15-DQB1*06. In addition, we also found that HLA-DRB1/DQB1 class II alleles DRB1*07,
DRB1*13, DQB1*03, genotypes DRB1*13/*11, DQB1*05/*03 and haplotypes DRB1*13-DQB1*06
and DRB1*11-DQB1*03 are associated with the protection against MS development. We cannot
exclude that the proposed protective effects of the DRB1*11-DQB1*03 and DRB1*13-DQB1*06
haplotypes in our cohort could be, at least partially, due to the linkagedisequilibrium with
alleles in the HLA class I region which is primarily associated with MS [41].
5. Non-HLA genes and MS
Gene products of non-HLA genes can contribute to the genetic risk of MS by modulation of
different processes. These genes are involved in the regulation of functions of T- and Bcells,
dendritic cells, NKcells, cytokine signalization, metabolism of interferons, vitamin D metab‐
olism, neuronal regeneration and many others [3]. It has been found that these genes can
contribute not only to the increased inherited risk of MS development but also to the risk of
other autoimmune diseases [42, 43]. The examples of the SNPs involved in the etiopathogenesis
of MS are summarised in Table 1.
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Gene function Localization SNP Alleles
HLA-DRB1*1501(human leucocyte antigen
DRB1*1501)
Antigen presentation 6p21 rs3135388 C/T
rs3135005 C/T
IL-7Ra (interleukin 7 receptor receptor alpha
chain)
Proliferation of memory Tcells, T-
and B-cell development
5p13 rs6897932 C/T
IL-2Ra (interleukin 2 receptor receptor alpha
chain)
Sensitization of Tcells to IL-2,
proliferation of Tcells
10p15 rs2104286 A/G
rs12722489 A/G
rs11256369 C/G
rs7076103 C/T
CD58 (cluster of differentiation 58) Function of regulatory Tcells 1p13 rs2300747 A/G
rs6677309 A/C
rs12044852 A/C
CD6(cluster of differentiation 6) Regulation, adhesion of TH17 and
other Tcells
11q13 rs17824933 C/G
rs12288280 G/T
CLEC16A (C-type lectin domain family 16
member A)
Cell receptor, induction of immune
response
16p13 rs6498169 A/G
rs12708716 A/G
VAV1 (vav guanine nucleotide
exchange factor 1)
Lymphocyte survival,
differentiation and proliferation
19p13 rs2546133 C/T
rs2617822 A/G
PRKCA (protein kinase C alpha) Regulation of IL-2 expression,
receptor
17q22-q23 Allele variants
in introns 3, 8
EVI 5 (ecotropic viral integration site 5 protein
homolog)
Nuclear protein, cell cycle
regulation
1p22 rs6680578 A/T
rs11808092 A/C
rs11804321 C/T
IRF5 (interferon regulatory factor 5) Regulation of cytokine activation 7q32 rs4728142 A/G
rs3807306 A/C
IRF8 (interferon regulatory factor8) Expression of interferon response
genes, development of Bcells
16q24 rs17445836 A/G
TYK2 (tyrosin kinase 2) Gene expression 19p13 rs34536443 C/G
rs55762744 C/T
TNFRSF1A (tumour necrosis factor receptor
superfamily member 1A)
Receptor for tumour necrosis factor 12p13 rs1800693 A/G
rs4149584 A/C/G
rs767455 C/T
rs4149577 C/T
CD40 (cluster of differentiation 40) Receptor for tumour necrosis factor 20q12-q13 rs1883832 C/T
CD226 (cluster of differentiation 226) Activator of NKcells, lymphocyte
adhesion, co-stimulator of Tcells
18q22 rs763361 C/T
KIF1B (kinesin family member 1B) kinesin
family member 1B)
Neuronal regeneration 1p36 rs10492972 C/T
GPC 5 (glypicane 5) Neuronal growth and reparation 13q32 rs9523762 A/G
Table 1. Gene polymorphisms involved in the etiopathogenesis of MS [3, 44–48].
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6. Genetic variants in interleukin 7 receptor α chain (IL-7Ra) gene
IL7 is a type 1 short-chain cytokine of the haematopoietin family involved in the modulation
of T- and B-cell development and T-cell homeostasis. To perform the immune system func‐
tions, IL7 binds to the transmembrane receptor that is formed by heterodimerisingthe common
cytokine gamma chain and IL7 receptor alpha chain (IL7Ra or CD127). IL7Ra is a membrane
glycoprotein folded to bind and mediate the action of IL7 and other alpha helical cytokines.
IL7Ra consists of an extracellular domain, transmembrane region and cytoplasmic tail, which
uses kinases for signal transduction [49]. The localization of the IL7Ra gene is chromosome
5p13.3. An increased expression of IL7Ra in peripheral blood mononuclear cells was found in
MS patients when compared to controls [50, 51]. The IL7Ra and IL7 mRNA increased expres‐
sion was found also in the cerebrospinal fluid of MS patients, possibly suggesting an altered
balance between the isoforms of IL7Ra and a higher signal-inducing immune cell proliferation
and survival [52]. According to the alternative splicing of exon 6 in IL7Ra gene, membrane-
bound or soluble isoforms of IL-7Ra are produced [53]. A significantly increased ratio of the
membrane-bound to soluble isoforms of IL7Ra in MS patients can facilitate the aberrant
activation of potentially auto-reactive T cells [54].
Single-nucleotide polymorphisms in IL7Ra gene are involved in the dysregulation of immune
homeostasis and thus can be associated with susceptibility to MS [55]. A genome-wide study
in a large group of subjects from the UK and USA identified the strong association between
SNP rs6897932 in IL7Ra gene and the risk of MS [2]. The non-conservative aminoacid change
on position 244 (Ile→Thr) ofIL7Ra is a result of the SNP rs6897932 (ATC → ACC) in exon 6 of
IL7Ra gene [56]. This aminoacid change has a functional effect on the product of expression of
alternative spliced IL7Ra gene, which is manifested by changes in the proportion of the soluble
versus membrane-bound isoforms of IL7Ra. The change of this ratio can be followed by a
different regulation of the IL7 signal transduction pathway and directly associates the SNP
rs6897932 with MS [57].
It has been found that allele C of SNP rs6897932 in IL7Ra gene contributes to the increased
genetic risk of MS in groups of MS patients from the USA [57, 58], South Spain [59], Nordic
countries—Denmark, Finland, Norway and Sweden [52], France [60], Netherlands [61] and
Japan [62]. The homozygosity for C allele was identified as a risk genotype for MS susceptibility
in Netherlands [61] and Spain [59]. A genotype association was also confirmed by the finding
of increased counts of CC genotype of rs6897932 in MS patients compared to controls in the
cohorts from the USA [58] and Japan [62]. Corresponding with the contribution of allele C to
the risk of MS, the protective effect of allele T for MS risk in a Nordic case-control group has
been reported by Lundmark et al. [52]. The protective effect of allele T has been reported also
in Spain by Alcina et al. [59]. On the contrary, no association between SNP rs6897932 and MS
was found in cohorts of MS patients from Northern Ireland [58], Germany [44] and Western
Balkan countries—Serbia, Croatia and Slovenia [63].
Only a few studies addressed the question whether the rs6897932 in IL7Ra gene contributes
only to the genetic risk of MS, or whether it can also affect the disease course and disability
progression [44, 57, 61, 64]. Groups of patients with different forms of MS were compared in
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several studies. In Northern European primary-progressive MS cases (PP MS), the underex‐
pression of IL7Ra gene as well as different allele frequencies of IL7Ra promoter SNP was
confirmed. Moreover, IL7Ra gene expression was found to be up-regulated in secondary-
progressive MS (SP MS) patients [64]. In a study by Akkad et al. [44] in German MS patients,
it was found that the soluble IL7Ra reduced the expression and allelic and genotypic associa‐
tion between rs6897932 and SP or PP MS but not with RR MS. In their study, a significantly
higher frequency of allele C and genotype CC of rs6897932 in SP and PP MS patients was found,
but not in RR MS patients compared to controls. The assessment of the severity of MS by MSSS
did not show any association between rs6897932 genotype and disease severity in the USA
[57]. Differences in allele frequencies in SP MS patients compared to healthy controls were
reported in Dutch MS patients by Sombekke et al. [61]. In spite of that, no association between
rs6897932 genotype and disease severity (MSSS, EDSS, other clinical tests) and disease activity
(relapse rate and MRI markers) was found.
Results of our own work suggest the relevance of rs6897932 allele and gene variants in MS
pathogenesis in Slovaks [10]. Our results have revealed that allele C is present in a higher
frequency in MS patients (77.4%) as compared to the control group (72.3%), which indicates
an increased risk of MS development (OR=1.314, 95% CI=1.004–1.720, p=0.047). Interestingly,
allele T was manifested in MS patients in a significantly lower frequency representing only
22.6% as compared to 27.7% in controls. This suggeststhat allele T seems to be protective
against MS development (OR = 0.761, 95% CI= 0.582–0.996, p = 0.047). The additive model fitted
the best to assess association between genotypes and MS risk. Logistic regression analysis
adjusted for sex and age revealed that there is a significant associationbetween IL7Ra rs6897932
genotype and MS risk (OR = 0.764, 95% CI = 0.586–0.995, plog = 0.045). The genotype analysis
showed that MS patients manifested a lower frequency of genotype CT when compared to
controls (34.8% vs. 36.3) and genotype TT (5.2% vs. 9.9%) and a higher frequency of genotype
CC (60.0% vs. 54.1%). When we used the additive genetic model, we found a significantly
decreased risk of MS development in carriers of allele T with genotype CT (OR = 0.865, 95%
CI = 0.609–1.228, p = 0.05) as well as with genotype TT (OR = 0.565, 95% CI = 0.282–1.132, p =
0.05).
After stratification of MS patients according to the disease disability progression rate, we found
a significantly lower frequency of allele T in the subgroup of rapidly progressing MS patients
(18.1%) as compared to 27.7% in controls. These results suggest that allele T is associated with
protection against rapid disability progression of MS (OR = 0.576, 95% CI = 0.348–0.955, p =
0.031). An additive genetic model adjusted for sex and age fitted the best to assess the associ‐
ation between genotypes and the rate of disease disability progression. Linear logistic regres‐
sion with disease disability rate as the dependent variable—MSSS (1, 2, 3 and 0 for controls)
revealed that there is a significant association between IL7Ra rs6897932 genotype and disability
progression of MS (plog = 0.034). Genotype analysis showed that the frequency of genotype TT
is higher in controls (9.6%) and lower in MS patients with rapid disability progression (3.5%).
Frequency of genotype CC was higher in rapidly progressing MS patients (67.2%) and lower
in controls (54.1%). The data suggest that individuals carrying genotype TT are protected
against rapid disease disability progression of MS.
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We have shown for the first time in a Central European Slovak population that allele C of
rs6897932 is associated with the risk of MS, and allele T has a protective additive effect against
MS susceptibility. Moreover,we revealed that minor allele T and genotype TT of rs6897932 in
the IL7Ra gene are protective against rapid disease disability progression in MS [65].
7. Vitamin D and its role in risk and progression of multiple sclerosis
In the past decades, much attention has been given to vitamin D and its role in MS and other
autoimmune diseases. The following sectionsare dedicated to the metabolism and structure
of vitamin D, its immunological effects, serum level and mechanisms of action of vitamin D
in the prevention and treatment of MS. We also describe the genetic factors that can modulate
the biological effects of vitamin D.
7.1. The structure and metabolism of vitamin D
Vitamin D in the human body undergoes a complex metabolism. Cholecalciferol (vitamin
D3), as a precursor of a hormonally active form, is produced in the skin from 7-dehydrocho‐
lesterol after sunlight exposure and can also be absorbed from the diet. Subsequently, chole‐
calciferol is hydroxylated in the liver forming 25-hydroxycholecalciferol, calcidiol. The
hormonally active form of vitamin D, 1,25- dihydroxycholecalciferol, calcitriol, is produced
by further hydroxylation especially in the kidneys and also in other tissues. The enzyme cat‐
alysing this hydroxylation is 25-hydroxyvitamin D-1α-hydroxylase, coded by CYP27B1 (cy‐
tochrome P450 family 27 subfamily B member 1) gene [66, 67]. In various cells, the bioactive
form of vitamin D binds to the vitamin D receptor (VDR) providing its physiological func‐
tions by modulation of the target gene’s transcription [68]. The circulating serum level of vi‐
tamin D depends not only on environmental factors such as exposition to sunlight and
vitamin D intake but also on genetic and epigenetic factors.The genetic factors can influence
the effects of vitamin D through the variability of the genes participating in its activation
and degradation, transport and receptor signalling [69].
7.2. The effect of vitamin D on the functions of immune cells
There is growing evidence that vitamin D not only regulates bone metabolism but also has
large-scale immunomodulatory and anti-inflammatory effects. A linkage has been found be‐
tween vitamin D deficiency and increased risk of autoimmune diseases [70]. The immuno‐
competent cells—macrophages, dendritic cells, Tcells and Bcells are able to produce
calcitriol and express the VDR at the high rate. Through this, vitamin D modulates the syn‐
thesis of various cytokines and immunoglobulins and is involved in the regulation of innate
and adaptive immune response. Autocrine and paracrine effects of vitamin D depend also
on its serum level, and individuals with hypovitaminosis D are in a state of immune system
dysfunction and are predisposed to the development of autoimmune diseases [71].
In Tcells, calcitriol inhibits the production of IL-12 and IFN-γ and subsequent differentiation
of TH1 lymphocytes that are the key cells involved in the MS development. Calcitriol improves
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the immunosuppressive functions of TREGcells and ameliorates the TH2-cell development by
the activation of the promotor region of IL-4 gene [19, 72]. Vitamin D increases the expression
of IL-4, IL-5 and IL-10 that are able to activate TH2 cells, decreases the production of IFN-γ,
blocks the formation of TH1cells after antigen stimulation and has positive effects on the TH1-
mediated autoimmune diseases [73, 74]. Bcells, which also participate in the demyelinating
process and produce intrathecalimmunoglobulins, express VDR and vitamin D hydroxylases.
In Bcells, calcitriol reduces the intracellular signal pathways of nuclear transcription factor NF-
kappa B (NF-kB) and CD40 signalling [75]. Calcitriol inhibits the maturation and proliferation
of Bcells, induces apoptosis of Bcells, inhibits the differentiation of plasma and memory cells
and decreases the production of immunoglobulinsIgG and IgM [76]. Immature Bcells are more
prone to regulation by calcitriol when compared to plasma cells. Calcitriol also decreases the
expression of MHCII molecules and co-stimulatory molecules in Bcells [19].
Calcitriol formed in macrophages inhibits the immune response by suppressing proliferation
of TH1- and TH17cells and promoting the functions of TH2- and TREGcells [71]. Calcitriol inhibits
the secretion of IL-12 by antigen-presenting cells and monocytes [77]. Vitamin D blocks the
differentiation of immature dendritic cells and the expression of co-stimulatory molecules
CD40, CD80, CD86 and MHC II, thus decreasing the capacity of dendritic cells to activate
autoreactive Tcells. Vitamin D also ameliorates the spontaneous apoptosis of mature dendritic
cells [73]. In macrophages, calcitriolsuppresses intracellular oxidative burst and listericidal
activity. It also suppresses the expression of Fc and TLR receptors induced by IFN-γ that are
important for antigen recognition [78]. Vitamin D suppresses the proliferation of antigen-
specific Tcells and chemotaxisof dendritic cells by decreasing the expression of differentiation
antigens CD80, CD86 and HLA-DR molecules [79].
7.3. The murine model of MS and vitamin D
In mice that lack the VDR gene or the gene of the enzyme catalysing vitamin D activation, an
abnormal development and function of TH1-lymphocytes and deficiency of peripheral T-
lymphocytes have been observed [80, 81]. Calcitriol treatment can prevent the induction and
progression of autoimmune diseases including experimental autoimmune encephalomyelitis
(EAE), a murine model of MS [82, 83]. Calcitriol can also decrease the severity of EAE symp‐
toms, and its deficiency causes an increased susceptibility of animals to EAE induction [77,
82]. In mice with chronic EAE, vitamin D administration suppresses the proliferation of specific
TH1 cells, inhibits IL-12 dependent production of IFN-γ, prevents relapses and reduces
perivascular infiltration, demyelination plaque formation and axonal degeneration in the brain
and spinal cord [84].
7.4. Serum level of vitamin D and dose management
To reflect vitamin D status in the human body, calcidiol plasma level measurement is usually
used. Calcidiol is the main circulating form of vitamin D in plasma, and its biological half-time
is 19 days [85]. The recommended daily dose of vitamin D is approximately 10times higher
than in the past. The optimal serum level of vitamin D is 75–250 nmol/l (30–100 ng/ml). In
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countries with less sunny climate, the necessary daily dose of vitamin D is 1000–4000 IU/day
(1 μg = 40 IU) [86].
The risk of vitamin D overdosing is hypercalcaemia and subsequent organ and tissue damage.
Whole body exposure to sunlight results in the production of around 10,000 IU of vitamin D,
so it is not simple to cause vitamin D intoxication by its short-term peroral supplementation.
The results of several studies suggest that even high-dose vitamin D3 supplementation in MS
patients is safe and clinically useful. Burton et al. [87] administered high peroral doses of
vitamin D to healthy individuals and MS patients. The initial dose was 40,000 IU/dayduring
28 weeks, followed by 10,000 IU/day during 12 weeks; later it was gradually decreased to 0
IU/day, combined with 1.2 grams of calcium per day. During the period of 40,000 IU of vitamin
D per day, the serum levels reached 413 nmol/l, which was higher than the conventional limit
established for vitamin D toxicity (250 nmol/l). Calcidiol serum levels remained around this
limit for 18 weeks without any observed negative effects. The serum level of calcium was in
the physiological reference range during the whole study duration. Moreover, no cardiac
rhythm abnormalities or impairment of hepatic or renal functions was observed. Kimball et
al. [88] administered 4000–40,000 IU/day to patients in the active phase of MS together with
1.2 grams of calcium. Medium serum level of calcidiol was 78 ± 35 nmol/l and rose to 386 ± 157
nmol/l. Serum calcium level and urinary calcium to creatinine ratio did not exceed the
physiological reference values. Vitamin D supplementation in this study did not cause any
change in the serum level of hepatic enzymes, creatinine, electrolytes, proteins and parathor‐
mone. Although the serum level of calcidiol doubled the physiological upper range value,
hypercalcaemia or hypercalciuria was not observed.
Although the significant toxicity of vitamin D3 was not observed even in doses of 40,000 IU/
day, its daily dose in healthy individuals should not exceed 2000 IU. The optimal daily dose
of vitamin D3 that should be routinely recommended to women during pregnancy and
lactation is 1000 IU. Children born in families with MS history should be administered daily
200–400 IU of vitamin D3 [66].
7.5. Vitamin D and the course, prevention and treatment of MS
The role of vitamin D in the prevention of MS development has been confirmed by many
experimental, epidemiological, genetic and immunological studies. Vitamin D insufficiency
during the whitematter development can alter the pathways of axonal differentiation and
adhesion and increase the apoptosis of oligodendrocytes that express VDR. This results in
local microenvironmental changes and altered regeneratory and remyelinating capacity [66].
In individuals with an increased genetic risk of MS, it is possible to prevent the demyelina‐
tion process by preventive vitamin D administration. This preventive strategy would be bet‐
ter than reparation of already developed myelin and axonal damage [12, 66].
High-dose peroral vitamin D intake has been found to be inversely associated with the risk of
MS in a cohort of more than 90,000 women. Peroral vitamin D supplementation in a dose higher
than 400 IU/day leads to the reduction of MS risk when compared to the individuals with no
vitamin D intake (RR = 0.59, 95% CI = 0.38–0.91,p = 0.006) [89]. Also,calcidiol plasma levels are
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inversely correlated with MS risk. This association is particularly obvious in whites, while
among blacks and Hispanics with lower 25-hydroxyvitamin D levels than whites, there was
no significant association between vitamin D and MS risk [90]. Vitamin D also has reparative
effects for the nervous tissue, especially in patients in the early phases of the disease. In
countries with low sun exposure, food supplementation of vitamin D could be a simple and
cheap method of MS prevention [86]. The incidence of MS could be reduced by the adminis‐
tration of vitamin D to pregnant women, and all children living in mild climates should be
more exposed to sunlight and should be on a vitamin D–rich diet [66].
Vitamin D is not only a factor modifying MS risk, but it can also have a role in the modulation
of disease course. It has been observed that in relapsing remitting MS, calcidiol plasma levels
are lower during relapses compared to the periods of remission [91]. In addition, there is
evidence that lower calcidiol levels are associated with higher relapse rates and higher risk of
exacerbation, as well as higher expanded disability status scale (EDSS) scores and progressive
forms of MS [92–94]. Vitamin D can improve memory and cognitive impairments in patients
with MS, Alzheimer disease and in patients after chemotherapeutical treatment [95]. High-
dose peroral vitamin D supplementation has immunomodulatory effects and leads to reduc‐
tion in the number of relapses and suppression of the inflammatory activity and proliferation
of Tcells [87], as well as the decrease in the number of gadolinium-enhancing lesions in brain
[88].
In our study, we examined the serum levels of calcidiol in a group of MS patients from the
Central-Northern part of Slovakia. We found that hypovitaminosis D is more frequent in MS
patients, when compared to healthy individuals. Serum levels of calcidiol were significantly
lower in MS patients when compared to controls (15.0 ± 6.1 ng/ml vs. 18.2 ± 8.3 ng/ml, p(K−W)=
0.001). Moreover, we found that there is an association of the serum level of vitamin D with
the rate of MS disability progression (p(K−W) = 0.000). We detected similar serum levels of
calcidiol in slow progressing and mid-rate progressing MS patients (15.7 ± 5.0 ng/ml vs. 15.8
± 6.6 ng/ml), but interestingly we noticed a marked decrease of calcidiol serum levels in rapidly
progressing MS patients (12.8 ± 5.9 ng/ml). In addition, calcidiol levelwas significantly lower
in all subgroups of MS patients when compared to controls (18.2 ± 8.3 ng/ml). Thus we can
conclude that decreased serum level of calcidiol in MS patients can be one of the factors related
to increased risk of MS development, as well as increased risk of rapid disease disability
progression.
7.6. Genetic factors related to vitamin D effects in MS
Nucleotide exchange in DNA sequence can cause the production of protein products with
different activities. Polymorphisms of the genes involved in the activation, transport, signal‐
ling and degradation of vitamin D can, together with other factors, modify the individual
immune response and thus can be related to MS. Because of the beneficial effects of vitamin
D, in individuals with genes predisposing to its higher serum levels, the risk of MS should be
reduced [96]. The serum level of vitamin D can be modified by VDR gene polymorphisms [97–
99]. The fact that serum levels of vitamin D are similar in twins, and especially when they are
monozygotic twins, speaks in favour of a genetic regulation. Gene polymorphisms FokI in
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VDR gene, rs4646536 and rs703842 in the CYP27B1 gene and rs10741657 in the CYP2R1 gene
are the significant predictors of caldiciol serum level [99]. Hypovitaminosis D is common in
higher latitudes because of the lack of sun exposure [100]. The fact that not all vitamin D–
deficient individuals develop MS is probably the result of the complexity of the etiopathoge‐
neis of MS and the interaction of many factors. The positive effects of vitamin D in MS can be
dampened for example by the allele HLA-DRB1*15 [96]. In MS patients, it is necessary to find
out the link between the genotype and the vitamin D serum level and also the genetic inter‐
actions among the genes CYP27B1, VDR and HLA [19]. The gene polymorphisms associated
with vitamin D metabolism are summarized in Table 2.
Gene function Localization  SNP Allele
CYP27B1 (cytochrome P450 family 27 subfamily
B member 1, 25-hydroxyvitamin D3
1-alpha-hydroxylase)
Hydroxylation 12q13 rs703842 C/T
rs10877012 G/C
rs4646536 C/T
rs10877015 A/G
rs118204009 A/G
rs118204012 A/G
rs118204011 C/T
CYP2R1 (cytochrome P450 family 2 subfamily
R member 1, vitamin D325-hydroxylase)
Hydroxylation 11p15 rs10741657 A/G
rs10500804 G/T
rs12794714 A/G
DBP (vitamin D binding protein) Transport in plasma 4q12 rs7041 G/T
rs4588 A/C
VDR (vitamin D receptor) Receptor 12q13 rs1544410 (BsmI) A/G (B/b)
rs7975232 (ApaI) T/C (A/a)
rs731236 (TaqI) T/C (T/t)
rs10735810 (FokI) C/T (F/f)
rs11568820 (Cdx2) G/A
rs2254210 A/G
rs98784 C/T
CYP24A1 (cytochrome P450 family 24 subfamily A
polypeptide, vitamin D 24-hydroxylase)
Deactivation 20q13 rs2296241 A/G
Table 2. The gene polymorphisms associated with vitamin D metabolism [19, 98, 99, 101].
7.6.1. Genetic variants in vitamin D receptor gene in MS
According to the effects of vitamin D in MS, the molecular mechanisms of vitamin D function
should be considered. As mentioned earlier, vitamin D executes its physiological effect via
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binding and activation of VDR. Interestingly, the activation of VDR by calcitriol can suppress
the induction of EAE, while animals that lack VDR are not protected against EAE [102]. The
gene for VDR is located on the 12q13 chromosomal region and consists of 11 exons. Non-coding
exons 1A, 1B and 1C are located in the 5′ end of the VDR gene, and exons 2–9 encode the
structural portion of the VDR protein [103]. VDR sequence is similar to that of the receptors
for steroid hormones and hormones of the thyroid gland. VDR is a regulatory transcription
factor and consists of highly conservative DNA-binding and ligand-binding domains. The
signal pathways associated with the VDR regulate the transcription of genes involved in the
regulation of bone metabolism, immune response and cancer [83]. The polymorphisms in the
initiation codon of the VDR gene can cause the formation of transcription variants coding
different proteins [104]. In the VDR gene, SNPs ApaI (rs7975232), BsmI (rs1544410), FokI
(rs10735810) and TaqI (rs731236) have functional biological effects and are mostly studied in
MS as well as in other diseases. These gene polymorphisms can alter mRNA level, its stability
and alternative splicingand also the stability of the final gene product, amount of protein
isoforms and their interactions [105]. FokI gene polymorphism is located in exon 2 of the VDR
gene, and its variants result in a change of protein structure. There are two possible allele
variants, f (presence of a restriction site for FokI endonuclease) and F (absence of a restriction
site for FokI endonuclease). It has been confirmed that the f (T) allele leads to the expression
of a VDR protein, which is three amino acids longer (427 amino acids) than the F (C) allele (424
amino acids). The shorter isoform of the receptor is more transcriptionally potent through a
more efficient interaction with transcription factor TFIIB [105, 106]. Near the 3′ end of the VDR
gene, we can find the ApaI and BsmI polymorphism in the intron between exon 8 and 9 and
TaqI gene polymorphism in exon 9 [107]. The allele variants of these gene polymorphisms and
their combinations regulate the functions of VDR through the modulation of mRNA stability.
In Caucasians, TaqI, ApaI and BsmI polymorphisms are in strong linkage disequilibrium and
are present in five haplotype blocks. Haplotype2 (t-A-B) probably results in a lower number
of 'A' in polyA variable number of tandem repeats (VNTR), while haplotype 1 (T-A-b) is
connected to a large number of 'A', thus modulating mRNA stability [106]. Morrison et al. [108]
found that allele b (G) of the BsmI polymorphism causes a decreased expression of VDR
mRNA.
Interestingly, several studies have found an association between VDR gene polymorphisms
and the risk of MS. Differences in allele frequency of the BsmI polymorphism in the VDR gene
were found in Japan by Fukazawa et al. [109], who for the first time pointed out the involve‐
ment of VDR gene polymorphisms in the pathogenesis of MS. The association of VDR gene
polymorphisms with MS has been confirmed in cohorts of MS patients from Japan [110], theUK
[111, 112], Australia [107] and the USA [98]. On the contrary, no association of VDR gene
polymorphisms with the risk of MS was found by studies in MS patients from Canada [113],
Netherlands [114], Greece [115], Spain [116, 117], Tasmania [118] and Iran [119]. The presence
of specific haplotypes of the VDR gene can increase the risk of MS development, especially its
progressive forms. Tajouri et al. [107] in Australia found haplotype A-t (T-C) of ApaI and TaqI
polymorphism to increase the risk of MS development, especially its progressive forms. The
carriership of allele t (C) in their study increased MS risk twice. Fukazawa et al. [109] found
allele b (G) and genotype bb (GG) of BsmI polymorphism to increase MS risk, but without any
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association with the form and severity of MS (EDSS, magnetic resonance imaging (MRI)). Allele
b (G) of BsmI polymorphism of VDR has been found to be associated with MS risk in combi‐
nation with allele A (T) of ApaI polymorphism by Niino et al. [110]. However, in their study,
they did not find any association of ApaI gene polymorphism with clinical form and severity
of MS evaluated by the EDSS score, disease duration and MRI findings. Agliardi et al. [120] in
Italy found that allele T (T) and genotype TT (TT) are protective against MS development,
supported by the finding that the expression of VDR mRNA is increased four times by
genotype Tt (TC) and eight times by genotype TT (TT) when compared to genotype tt (CC).
The observed effect is present especially when the protective allele Tis present in the combi‐
nation with HLA-DRB1*15 allele.
The role of VDR gene polymorphisms is still not completely understood, and it seems to vary
among different populations. For proper cell signalling to decrease the risk of MS, it is probably
necessary to reach a certain level of the transcriptional activity of VDR that is also modified
genetically. For proper immunoregulation, the individuals that have the genotype causing the
decreased VDR protein activity can need a higher peroral vitamin D intake or higher level of
sun exposure. Contrarily, in individuals with higher transcriptional activity of VDR, a lower
sun exposure or vitamin D intake can be sufficient for proper immune system regulation.
The findings of our previous study in MS patients from the Central-Northern region of
Slovakia have confirmed the association of FokI heterozygous genotype Ff with an increased
risk of MS in women [10]. Although we found no statistically significant differences in the
proportions of FokI genotypes or allele frequencies between total MS patient and the control
group, we have observed significant differences in the FokI genotype distribution between
women with MS and the female control group (p = 0.042). Our results have shown a signifi‐
cantly higher frequency of heterozygous Ff genotypes in FokI polymorphism in the female MS
group (53.4%) as compared to 43.7% in the female control group (OR = 1.48, 95% CI = 1.01–
2.16). In spite of this fact, when we compared the subgroup of rapidly progressing MS patients
with the subgroup of slow progressing MS patients, allele and genotype counts were not
significantly different between them (allele f: 34.5 vs. 43.3%, allele F: 65.5 vs. 56.7%, genotype
ff: 10.3 vs. 13.4%, genotype Ff: 48.3 vs. 59.8%). Since we have not shown any significant
association between FokI VDR gene polymorphism and the rate of disease disability progres‐
sion in our cohort of Slovak MS patients, we observed a trend of higher frequency of homo‐
zygotes FF to be 41.4% in MS patients with rapid progression of disease as compared to 26.8%
in slow progressing MS patients (OR = 1.93, 95% CI=0.94–3.94) with a marginal level of
significance (p = 0.071). From the results of our study, it seems that contributions from genetic
and allelic variants of FokI VDR gene polymorphism have only a small impact in a disease as
complex as MS, andits role in the etiopathogenesis of MS still remains controversial.
8. Conclusions
In summary, we can conclude that many genetic and biochemical factors can be involved in
the etiopathogenesis of MS. These markers could be used to evaluate the risk of MS develop‐
ment and the risk of rapid disease disability progression.
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The proposed markers that have been found to be associated with MS risk or disability pro‐
gression in Central European Slovak population are summarized in Table 3. In our studies,
we identified decreased serum level of vitamin D, allele C and genotype CC of polymor‐
phism rs6897932 in the IL7Ra gene, genotype Ff of rs10735810 in the VDR gene (only in
women); HLA-alleles DRB1*15, DRB1*03, DQB1*06; HLA-genotypes DRB1*15/*15,
DQB1*06/*06 and HLA-haplotype DRB1*15-DQB1*06 as the main risk factors for MS devel‐
opment. On the contrary, allele T of rs6897932 in the IL7Ra gene (in individuals with geno‐
type CT and TT); HLA-alleles DRB1*07, DRB1*13, DQB1*03; HLA-genotypes DRB1*13/*11,
DQB1*05/*03 and HLA-haplotypes DRB1*13-DQB1*06 and DRB1*11-DQB1*03 displayed a
protective effect against MS development. Genotype CC of rs6897932 in the IL7Ra gene and
decreased serum level of vitamin D were identified as negative prognostic factors for rapid
disability progression in MS, while minor allele T of rs6897932 in the IL7Ra gene (especially
in individuals with TT genotype) was identified as a protective factor disability progression.
MS development Rapid disease disability progression
Risk
factors
Decreased serum vitamin D Decreased serum vitamin D
rs6897932 in IL7Ra gene—allele C,
genotype CC
rs6897932 in IL7Ra
gene—genotype CC
HLA-alleles DRB1*15, DRB1*03, DQB1*06;
HLA-genotypes DRB1*15/*15, DQB1*06/*06;
HLA-haplotype DRB1*15-DQB1*06
rs10735810 in VDR gene —genotype
Ff (only women)
Protective
factors
rs6897932 in IL7Ra gene—allele T,
genotype CT and TT
rs6897932 in IL7Ra gene—allele T,
genotype TT
HLA-alleles DRB1*07, DRB1*13, DQB1*03;
HLA-genotypes DRB1*13/*11, DQB1*05/*03;
HLA-haplotypes DRB1*13-DQB1*06, DRB1*11- DQB1*03
Table 3. The proposed markers associated with the MS risk or disability progression in Slovaks [10, 41, 65].
From the results of our study, we conclude that rs6897932 of the IL7Ragene, rs10735810 in the
VDR gene, HLA-DR and DQ genotypes, as well as serum level of vitamin D may be the
important markers that could be used as part of a panel of markers to evaluate the risk of MS
development and disability progression. The relevance of these markers identified in our study
should be verified in larger groups of individuals not only in Slovakia but also in other different
populations. The relevant positive or negative prognostic genetic or biochemical markers can
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improve the diagnostic and therapeutic procedure and can help to minimize neurological
damage in predisposed individuals.
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